Next Phase Newsletter

A US-based venture capital firm with a hands-on investment approach and a strong commitment to supporting underrepresented founders  invests at the Seed and Series A stages, typically leading rounds with initial check sizes of up to $2 million in equity. The firm makes approximately 1-3 new investments per year and focuses on companies based in the United States. 

Within life sciences, the firm invests in disruptive technologies in the medical device sector and is open to all classes of medical devices. 

The firm is dedicated to backing diverse founding teams. Its current portfolio includes a significant proportion of companies led by women and minorities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm based in Western Europe invests in healthcare companies with typical check sizes ranging from €1–20 million, usually entering at the second or third round of financing and participating through Series B. The firm focuses on companies based in the U.S. and Europe. 

The firm invests in diagnostics, digital health, and medical devices, but does not invest in drugs, biotech, or therapeutics. The firm targets companies in the in-development or clinical stages and is indication-agnostic. 

The firm does not have specific requirements for management teams and typically takes a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm with offices in the US typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity. 
 
The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures. 
 
The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A U.S. subsidiary of a China-headquartered enterprise focused on advanced manufacturing and technical services, medical and healthcare, trade, and engineering services. The firm is seeking investment opportunities in life sciences and healthcare. The firm is open to various deal structures, including equity investments, M&A, and joint ventures. 
 

For equity investments, the firm’s sweet spots are Series A and Series B, although the firm is capable of making later-stage investments. Typical check sizes range from $10M to $100M. While primarily focused on opportunities in the U.S., the firm is also open to investments in North and South America. 
 
The firm is most interested in biotech therapeutics and pharmaceuticals and remains opportunistic regarding modalities and indications. The firm typically evaluates assets in Phase I or Phase II. Other areas of interest include hospital products, especially those leveraging AI, as well as surgical tools and R&D research technologies. 
 
The firm does not have specific requirements for a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A privately funded investment firm based in Canada is focused on making direct investments in the following business sectors: medical technology, medical clinics, healthcare IT and healthcare real estate.  In medtech, the firm seeks to invest in seed stage companies.  The firm looks to partner and fund scientific founders to launch a new company and will primarily invest in the seed stage round. The firm typically allocates $100K-$200K, and will syndicate with other investors outside of their region to invest in larger rounds of $500K or more. The firm has physician, medical experience, particularly in the surgical field. The firm invests globally and is currently seeking new investment opportunities. 
 
In the life sciences, the firm is currently seeking to invest in medical devices and healthcare IT. The firm is opportunistic in terms of the class of device and indications, and has particular interest in surgical devices and tools. The firm is additionally interested in digital health, especially those with a software component. The firm prefers to invest in the pre-prototype stage and with particular preference to very early-stage preclinical technology. 
 
The firm is seeking startups with a maximum $5M pre-money valuation and will invest in pre-revenue companies. The firm is very hands-on after an investment, opening up and bringing their network to their portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A private family foundation dedicated to advancing brain tumor research employs a venture philanthropy investment model, which combines deep disease-focused expertise with funding for high-risk/high-reward opportunities. The foundation’s fund typically participates in seed to series A financing rounds with initial investment ranging from $250K to $1M and potential for follow-on investments. The fund is looking to make 3-5 investments per year, primarily within the US and Canada. As a subsidiary of the foundation, the fund will leverage the extensive network and expertise of the foundation and is active in supporting their portfolio companies. The fund does not typically lead rounds and more often co-invests. 
 
The fund focuses on primarily on brain tumor and will consider all technology types, including therapeutics, medical devices, and diagnostics. The fund will also consider adjacent spaces such as neuroscience, as long as there are potential implementations in brain cancer. The fund is also open to talking with companies that do not have a pipeline in brain cancer currently but have potential application in brain cancer in the future. The fund seeks to make investments that are impactful for the company, and typically prefers companies in pre-clinical or early clinical stages, especially for therapeutics. For diagnostics, the fund may consider assets that are in later stages of clinical development. 
 
An ideal founding team will have complementary skill sets, and expertise on the business or the fundraising front is a plus. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A US-based venture fund invests only in seed and pre-seed rounds, and focuses solely on opportunities in healthcare IT, medtech and consumer health. The firm primarily invests in U.S. based companies but can invest in any geography. 
 
The firm invests in very early stage companies across the healthcare innovation ecosystem, including healthcare IT, medical devices, and consumer health. The firm is highly interested in preventative healthcare, future of work and healthcare IT applications. The firm is open to investing in any area of medicine, but has specific interest in opportunities in cardiology, pulmonary diseases, diabetes, and women’s health. 
 
The firm does not invest in companies that have already raised over $5 million in dilutive capital. The firm seeks to invest in high quality management teams, and prefers to work with experienced entrepreneurs that have a proven track record in their sector. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology